Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Benha University

Status: Completed

Conditions: Posterior Uveitis

Treatments: Drug: Dexamethasone Ophthalmic implant

Study type: Observational

Funder types: Other

Identifiers

NCT03971279

hamaky2

Details and patient eligibility

About

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Full description

Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done.

Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

Enrollment: 16 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recurrent VKH posterior uveitis

Exclusion criteria

• retinal pathology, other causes of posterior uveitis